Alvotech Expands Agreement Scope into Biosimilar Development
Biosimilar development company Alvotech has entered into new agreements to expand its product development capacity and international reach.
Reykjavik-based biopharmaceutical company Alvotech has strengthened its position in the biosimilar market through new agreements covering multiple development stages.
The company has signed a letter of intent to develop and manufacture several biosimilars for a global pharmaceutical firm. This agreement includes options for additional products and spans the entire process from early development to commercialization. This strategic expansion allows Alvotech to offer its expertise more broadly and integrate a larger number of products into its development pipeline.
Concurrently, Alvotech has established a new collaboration with a leading Nordic pharmaceutical company. This partnership is set to commercialize Alvotech's biosimilars currently in development within specific European markets. The collaboration leverages the strengths of both companies in their respective regional areas.
These agreements underscore Alvotech's growth strategy and its capability to forge partnerships that support its objective of providing more accessible and affordable alternatives for biologic medicines used in treating complex conditions. The company aims to further broaden its product portfolio and global footprint within the biosimilar sector.